virus clearance in HPV+ patients. Cervical high risk human papillomavirus (HPV) DNA test positive
Conditions
Interventions
Intervention 1: Intervention group: Lactoferin Vaginal Tablet 300 mg ( produced in fanda pharma) to be used once daily by applicator at bedtime from 5th day of mense for 21 days. Intervention 2: Con
Sponsors
Pasture Institute of Iran
Eligibility
Sex/Gender
Female
Age
25 Years to 50 Years
Inclusion criteria
Inclusion criteria: Age: 25 to 50 years Gender: Female Marital Status: Married/Single HPV positive patients (genotypes 16, 18, 31, 33, 39, 45, and 52) Normal pap smear Low grade pathology / CIN1
Exclusion criteria
Exclusion criteria: Pregnant women observation of internal/external warts history of surgery ?alchohol consumption AIDS (HIV+) Drug use within 90 days People with systemic immunosuppressive disorders Patients who have received local or systemic treatment in the last three months. Abnormal pap smear High grade pathology Cancer Conization history Suffering from chronic diseases (diabetes, fatty liver and metabolic diseases, etc.) Having more than 3 sexual partners Patients with a history of treatment with Eldara and similar drugs (local and systemic) History of Allergy, sensitivity to medicine, Anaphylaxis shock
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV clearance in HPV+ after 6 months. Timepoint: 0-3-6 month. Method of measurement: hpv genotyping test.;Pap smear. Timepoint: 0-3-6 month. Method of measurement: cytology and pap smear. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNaghmeh Hadidi
Pasture Institute of Iran
Outcome results
None listed